文献速递眼底病与葡萄膜炎

糖尿病黄斑水肿玻璃体腔内药物治疗:美国眼科学会报告

Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2021-08-23

该报告综述了抗血管内皮生长因子(VEGF)药物和玻璃体腔皮质类固醇治疗糖尿病黄斑水肿(DME)的安全性和有效性证据。检索PubMed数据库后共纳入31篇文章,其中21篇为I级证据。结论认为抗VEGF药物和皮质类固醇注射均有效,但皮质类固醇可能引起眼压升高和白内障进展,需个体化选择治疗。

要点

  • 抗VEGF药物和玻璃体腔皮质类固醇均是DME的有效治疗。
  • 皮质类固醇治疗需警惕眼压升高和白内障进展。
  • 缺乏高质量比较疗效数据,治疗应个体化并保证广泛可及性。

核心结论

  • 玻璃体腔注射抗VEGF药物和皮质类固醇是糖尿病黄斑水肿的有效治疗。

研究设计与样本

  • 美国眼科学会报告,通过PubMed检索(截至2020年5月13日,无日期限制,英文文献),初检230篇,全文审阅108篇,最终纳入31篇并由方法学家进行证据分级。

主要发现

  • 仅21篇I级证据文章被纳入本评估。
  • 7篇文章为玻璃体腔皮质类固醇治疗DME提供I级证据:曲安奈德1篇、地塞米松4篇、氟轻松2篇。

关键数值与推荐

  • 抗VEGF药物包括雷珠单抗、阿柏西普和贝伐珠单抗。
  • 皮质类固醇包括曲安奈德、地塞米松和氟轻松。
  • 眼压升高和白内障进展是皮质类固醇治疗的重要潜在并发症。

临床怎么用

  • 临床选择治疗时需根据患者个体情况决定。
  • 确保患者能广泛获得治疗以最大化 outcomes。

局限性

  • 需要进一步证据评估这些治疗的比较疗效。
  • 高质量比较疗效数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the evidence on the safety and efficacy of current anti-vascular endothelial growth factor (VEGF) and intravitreal corticosteroid pharmacotherapies for the treatment of diabetic macular edema (DME). METHODS: Literature searches were last conducted on May 13, 2020, in the PubMed database with no date restrictions and limited to articles published in English. The combined searches yielded 230 citations, of which 108 were reviewed in full text. Of these, 31 were deemed appropriate for inclusion in this assessment and were assigned a level of evidence rating by the panel methodologist. RESULTS: Only the 21 articles with level I evidence were included in this assessment. Seventeen articles provided level I evidence for 1 or more anti-VEGF pharmacotherapies, including ranibizumab (14), aflibercept (5), and bevacizumab (2) alone or in combination with other treatments for DME. Level I evidence was identified in 7 articles on intravitreal corticosteroid therapy for treatment of DME: triamcinolone (1), dexamethasone (4), and fluocinolone acetonide (2). CONCLUSIONS: Review of the available literature indicates that intravitreal injections of anti-VEGF agents and corticosteroids are efficacious treatments for DME. Elevated intraocular pressure and cataract progression are important potential complications of corticosteroid therapy. Further evidence is required to assess the comparative efficacy of these therapies. Given the limited high-quality comparative efficacy data, choice of therapy must be individualized for each patient and broad therapeutic access for patients is critical to maximize outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ehlers JP, Yeh S, Maguire MG, et al. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology. 2021. PMID: 34446301. doi:10.1016/j.ophtha.2021.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。